Already a print subscriber? Activate your online access.
Browse our complete archive of Gastroenterology summaries
What prophylactic dose should be recommended?
Both active drugs tested produced higher cure rates than placebo.
New risk factors have been added to the QRISK calculator.
Colonoscopy and fecal immunochemical test are first-tier screening modalities.
Weight loss and several measure of cardiovascular risk were similar in both groups.
Observational data show a weak association without evidence of causality.
Patients on infliximab for a variety of indications had similar outcomes with infliximab or its biosimilar CT-P13 in a 1-year trial.
A sequential age-based approach to diagnosis and therapy is recommended.
An expert working group provides recommendations for practitioners.